Drug Profile
Buspirone controlled release - Mapi Pharma
Alternative Names: Buspirone ER - Mapi PharmaLatest Information Update: 19 Oct 2022
Price :
$50
*
At a glance
- Originator Mapi Pharma
- Developer Jiangsu Nhwa Pharmaceutical; Mapi Pharma
- Class Antidepressants; Anxiolytics; Pyrimidines; Small molecules; Spiro compounds
- Mechanism of Action 5-HT1A serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Schizophrenia
- No development reported Anxiety disorders
Most Recent Events
- 19 Oct 2022 Phase I development is ongoing in Israel (Mapi Pharma pipeline, October 2022)
- 19 Oct 2022 Phase-I clinical trials in Schizophrenia in Israel (PO) (Mapi Pharma pipeline, October 2022)
- 28 Nov 2021 No recent reports of development identified for preclinical development in Schizophrenia in Israel (PO, Controlled release)